Edwards Lifesciences Corporation $EW is Jacobs Levy Equity Management Inc.'s 9th Largest Position

Key Points

• Jacobs Levy Equity Management Inc. has reduced its position in Edwards Lifesciences Corporation by 5.5%, now owning approximately 4.36 million shares, which accounts for about 1.3% of its investment portfolio.
• Edwards Lifesciences reported a quarterly EPS of $0.67, exceeding analyst expectations, with revenue of $1.53 billion, an increase of 11.9% from the previous year.
• Institutional investors collectively hold 79.46% of Edwards Lifesciences' stock, with several firms adjusting their positions significantly during the first quarter.

Jacobs Levy Equity Management Inc. lessened its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 5.5% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 4,362,446 shares of the medical research company's stock after selling 252,717 shares during the period. Edwards Lifesciences makes up about 1.3% of Jacobs Levy Equity Management Inc.'s holdings, making the stock its 9th largest position. Jacobs Levy Equity Management Inc. owned 0.74% of Edwards Lifesciences worth $316,190,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Vega Investment Solutions acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $27,000. Quantbot Technologies LP acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $26,000. SouthState Corp acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $27,000. Rossby Financial LCC acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $29,000. Finally, Costello Asset Management INC acquired a new stake in Edwards Lifesciences in the first quarter valued at approximately $29,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on EW shares. The Goldman Sachs Group reissued a "buy" rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Deutsche Bank Aktiengesellschaft raised their target price on Edwards Lifesciences from $85.00 to $94.00 and gave the company a "buy" rating in a report on Friday, July 25th. Wall Street Zen upgraded Edwards Lifesciences from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 30th. BTIG Research upgraded Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a report on Tuesday, July 29th. Finally, Robert W. Baird raised their target price on Edwards Lifesciences from $78.00 to $79.00 and gave the company a "neutral" rating in a report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Stock Performance

Edwards Lifesciences stock traded down $0.37 during mid-day trading on Tuesday, reaching $79.84. 2,293,753 shares of the company's stock were exchanged, compared to its average volume of 4,438,283. The business's fifty day simple moving average is $78.80 and its 200 day simple moving average is $75.26. The firm has a market capitalization of $46.87 billion, a PE ratio of 11.49, a P/E/G ratio of 3.90 and a beta of 1.07. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the company posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the sale, the vice president directly owned 22,002 shares in the company, valued at $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,014 shares of company stock worth $1,698,844. Corporate insiders own 0.34% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.